Current treatments for Parkinson's still only provide symptomatic relief but Bayer AG is hopeful that a couple of its cell and gene therapies being developed by its wholly owned subsidiaries BlueRock Therapeutics LP and Asklepios BioPharmaceutical, Inc. could potentially offer a paradigm shift in tackling the disease.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?